Alterity Therapeutics Limited (ATHE) - מזומן למניה

The cash per share metric reflects the impact of stringent FDA oversight and high development costs, with 1.34 becoming the new value for this indicator. Alterity Therapeutics (ATHE) focuses on therapies for rare brain pathologies to save neurons. However, geopolitical instability and logistics disruptions in sanctioned regions create financial risks for conducting global trials.
פילוחי מדדים מקיפים ואנליטיקה עבור Alterity Therapeutics Ltd. (ATHE)

Cash per share is of key importance for assessing the financial stability of Alterity Therapeutics (ATHE). This indicator determines the portion of liquid assets attributable to a single security. The current value of 1.34 reflects the actual capital reserve available to support operational activities. For a biotech company without revenue, this calculation measures the cash burn rate for R&D projects. A steady decline in this metric signals the approaching need for recapitalization.